A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.
| XSGO Exchange | US Country |
The described company operates as an investment fund focused on tracking the performance of a specific underlying index. By investing at least 80% of its assets in the securities that comprise the index, the fund aims to mimic the index's returns and behavior closely. This strategy indicates a focus on providing investors with exposure to the components of a particular market or sector through the index it follows. However, it is noteworthy that the fund is characterized as non-diverse, which means it may concentrate its investments in a particular sector, company, or geographical area, potentially increasing the risk of volatility and loss due to lack of diversification.
The fund offers a targeted investment product that primarily focuses on securities from its underlying index, alongside additional financial instruments to potentially enhance returns and manage risks: